Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy

Abstract

Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.

We claim: 
     
         1 . A method of treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor, to thereby treat the cisplatin-induced peripheral neuropathy. 
     
     
         2 . The method of  claim 1 , wherein the histone deacetylase 6 selective inhibitor is compound 001: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         3 . The method of  claim 1 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin. 
     
     
         4 . The method of  claim 1 , wherein the histone deacetylase 6 selective inhibitor is administered before or after administering cisplatin. 
     
     
         5 . The method of  claim 1 , wherein the cisplatin-induced peripheral neuropathy exists in the subject prior to administering the histone deacetylase 6 selective inhibitor. 
     
     
         6 . A method of treating cisplatin-induced pain or cisplatin-induced numbness, comprising administering to a subject in need thereof an effective amount of a histone deacetylase 6 selective inhibitor to thereby treat the cisplatin-induced pain in the subject. 
     
     
         7 . The method of  claim 6 , wherein the histone deacetylase 6 selective inhibitor is compound 001: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         8 . The method of  claim 6 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin. 
     
     
         9 . The method of  claim 6 , wherein the histone deacetylase 6 selective inhibitor is administered before or after administering cisplatin. 
     
     
         10 . The method of  claim 6 , wherein the cisplatin-induced peripheral neuropathy exists in the subject prior to administering the histone deacetylase 6 selective inhibitor. 
     
     
         11 . A method for restoring the loss of intra-epidermal nerve fiber (IENF) in a subject, comprising administering to the subject an effective amount of a histone deacetylase 6 selective inhibitor. 
     
     
         12 . The method of  claim 11 , wherein the loss of intra-epidermal nerve fiber is the result of administering cisplatin to the subject. 
     
     
         13 . The method of  claim 12 , wherein the administration of the histone deacetylase 6 selective inhibitor to the subject occurs during or after administering cisplatin. 
     
     
         14 . The method of  claim 11 , wherein the histone deacetylase 6 selective inhibitor is compound 001: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof.